Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rheumatology

- PMLiVE

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global health

- PMLiVE

Effective Communication in Virtual Meetings: Stay Pithy – Impetus InSite Tips #4

Learn the value of concise communication in our fourth tip for optimizing virtual meetings. Discover how keeping interactions short and focused can drastically improve engagement and retention in today's fast-paced...

Impetus Digital

- PMLiVE

Pfizer shares positive late-stage results for RSV vaccine Abrysvo in high-risk adults

There are currently no vaccines approved for use in adults aged 18 to 59 years

- PMLiVE

Pfizer’s antibiotic combination receives CHMP recommendation to treat multidrug-resistant infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global public health

- PMLiVE

Do omnichannel approaches have a role in market access and payer discussions?

By Frank Fisher and Claire Woon

AMICULUM

- PMLiVE

Pfizer/Astellas’ Xtandi receives CHMP recommendation to treat recurrent prostate cancer

For nine out of ten patients with nmHSPC with high-risk BCR, their condition will progress into a metastatic disease

- PMLiVE

Sanofi and Owkin expand AI collaboration to include drug positioning in immunology

The expansion builds on the companies’ strategic alliance previously announced in 2021

- PMLiVE

UK survey reveals two-thirds of vitiligo patients struggle with mental health

The Vitiligo Society has launched a campaign to address the lack of awareness and understanding surrounding the condition

- PMLiVE

Mastering Asynchronous Meetings: Open-Ended Questions – Impetus Digital Tip 1

Unlock the potential of asynchronous virtual meetings with the first tip from our "Top 10 Tips for Optimizing Asynchronous Virtual Meetings".

Impetus Digital

- PMLiVE

Pfizer’s 20-valent pneumococcal vaccine receives EC approval for infants and children

The 20 serotypes included in Prevenar 20 cause the majority of circulating pneumococcal disease

- PMLiVE

Pfizer’s Adcetris combination shows promise in phase 3 large B-cell lymphoma study

The aggressive blood cancer affects more than 25,000 people in the US every year

- PMLiVE

Pfizer’s Velsipity receives MHRA and NICE authorisations to treat ulcerative colitis

The immune-mediated inflammatory bowel disease affects approximately 300,000 people in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links